R. Jean-philippe, PR) (69ème section) FRANCESCHI Frédéric (PU-PH)

B. Adriana, MCF) (69ème section) CHIRURGIE DIGESTIVE 5202

A. Zaineh and M. , MCF) (5ème section)

B. Sylvie, MCF) (5ème section) BEGE Thierry (MCU-PH)

B. Evelyne, MCF) 65ème section) (retraite octobre, 2016.

B. Françoise, MCF) 65ème section)

B. Caroline, MCF) (1ère section)

F. Simon, (. Pr, and . Méd, Gén. à mi-temps) BERLAND Yvon (PU-PH)

A. Sébastien, (. Mcf, and . Méd, Gén. à mi-temps) BURTEY Stépahne (PU-PH)

. Bonnet-pierre-andré and . Méd, Gén à mi-temps) MOAL Valérie (PU-PH)

G. Pierre and . Méd, Gén. à mi-temps) JOURDE CHICHE Noémie (MCU PH)

R. Stéphane, Professeur associé des universités mi-temps) PHILOSPHIE 17

L. Coz and P. , PR) (17ème section)

M. Kao, D. Ang, A. Pall, and A. Struthers, Oxidative stress in renal dysfunction: mechanisms, clinical sequelae and therapeutic options, Journal of Human Hypertension, vol.11, issue.1, pp.1-8, 2009.
DOI : 10.1016/j.ymgme.2004.03.006

URL : http://www.nature.com/jhh/journal/v24/n1/pdf/jhh200970a.pdf

F. Barreto, D. Barreto, S. Liabeuf, N. Meert, G. Glorieux et al., Serum Indoxyl Sulfate Is Associated with Vascular Disease and Mortality in Chronic Kidney Disease Patients, Clinical Journal of the American Society of Nephrology, vol.4, issue.10, pp.1551-1559, 2009.
DOI : 10.2215/CJN.03980609

URL : http://cjasn.asnjournals.org/content/4/10/1551.full.pdf

K. Wattanakit, M. Cushman, C. Stehman-breen, S. Heckbert, and A. Folsom, Chronic Kidney Disease Increases Risk for Venous Thromboembolism, Journal of the American Society of Nephrology, vol.19, issue.1, pp.135-175, 2008.
DOI : 10.1681/ASN.2007030308

URL : http://jasn.asnjournals.org/content/19/1/135.full.pdf

H. Rm, H. Gj, M. W. , D. H. , and A. D. , Major bleeding in hemodialysis patients, Clin J Am Soc Nephrol CJASN, vol.3, issue.1, pp.105-115, 2008.

R. Vanholder, D. Smet, R. Glorieux, G. Argilés, A. Baurmeister et al., Review on uremic toxins: Classification, concentration, and interindividual variability, Kidney International, vol.63, issue.5, pp.1934-1977, 2003.
DOI : 10.1046/j.1523-1755.2003.00924.x

URL : https://doi.org/10.1046/j.1523-1755.2003.00924.x

F. Duranton, G. Cohen, R. Smet, M. Rodriguez, J. Jankowski et al., Normal and Pathologic Concentrations of Uremic Toxins, Journal of the American Society of Nephrology, vol.23, issue.7, pp.1258-70, 2012.
DOI : 10.1681/ASN.2011121175

URL : http://jasn.asnjournals.org/content/23/7/1258.full.pdf

L. Dou, M. Sallee, C. Cerini, S. Poitevin, B. Gondouin et al., The Cardiovascular Effect of the Uremic Solute Indole-3 Acetic Acid, Journal of the American Society of Nephrology, vol.26, issue.4, 2015.
DOI : 10.1681/ASN.2013121283

URL : https://hal.archives-ouvertes.fr/hal-01610425

D. Zimmerman, M. Sood, C. Rigatto, R. Holden, S. Hiremath et al., Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis, Nephrology Dialysis Transplantation, vol.27, issue.10, pp.3816-3838, 2012.
DOI : 10.1093/ndt/gfs416

W. Winkelmayer, A. Patrick, J. Liu, M. Brookhart, and S. Setoguchi, The Increasing Prevalence of Atrial Fibrillation among Hemodialysis Patients, Journal of the American Society of Nephrology, vol.22, issue.2, pp.349-57, 2011.
DOI : 10.1681/ASN.2010050459

Z. Hijazi, S. Hohnloser, J. Oldgren, U. Andersson, S. Connolly et al., Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial FibrillationClinical Perspective. Circulation, pp.961-70, 2014.

R. Marinigh, D. Lane, and G. Lip, Severe Renal Impairment and Stroke Prevention in Atrial Fibrillation, Journal of the American College of Cardiology, vol.57, issue.12, pp.1339-1387, 2011.
DOI : 10.1016/j.jacc.2010.12.013

URL : https://doi.org/10.1016/j.jacc.2010.12.013

K. Dahal, S. Kunwar, J. Rijal, P. Schulman, and J. Lee, Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease, Chest, vol.149, issue.4, pp.951-960
DOI : 10.1378/chest.15-1719

J. Tan, S. Liu, J. Segal, G. Alexander, and M. Mcadams-demarco, Warfarin use and stroke, bleeding and mortality risk in patients with end stage renal disease and atrial fibrillation: a systematic review and meta-analysis, BMC Nephrology, vol.158, issue.9, p.157, 2016.
DOI : 10.1093/aje/kwg231

H. Van-der-meersch, D. Bacquer, D. , D. Vriese, and A. , Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: A systematic review and meta-analysis, American Heart Journal, vol.184, pp.37-46
DOI : 10.1016/j.ahj.2016.09.016

Z. Harel, G. Chertow, P. Shah, S. Harel, P. Dorian et al., Warfarin and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation Receiving Dialysis: A Systematic Review and Meta-analysis, Canadian Journal of Cardiology, vol.33, issue.6, pp.737-783, 2017.
DOI : 10.1016/j.cjca.2017.02.004

T. Wilkieson, A. Ingram, M. Crowther, S. Soroka, R. Nagai et al., Low-Intensity Adjusted-Dose Warfarin for the Prevention of Hemodialysis Catheter Failure: A Randomized, Controlled Trial, Clinical Journal of the American Society of Nephrology, vol.6, issue.5, pp.1018-1042, 2011.
DOI : 10.2215/CJN.07240810

M. Proietti, D. Lane, and G. Lip, Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF Trials, EBioMedicine, vol.8, pp.309-325
DOI : 10.1016/j.ebiom.2016.04.013

M. Kleinow, C. Garwood, J. Clemente, and P. Whittaker, Effect of Chronic Kidney Disease on Warfarin Management in a Pharmacist-Managed Anticoagulation Clinic, Journal of Managed Care Pharmacy, vol.17, issue.7, pp.523-553, 2011.
DOI : 10.18553/jmcp.2011.17.7.523

J. Kooiman, N. Rein, . Van, B. Spaans, K. Beers et al., Efficacy and Safety of Vitamin K-Antagonists (VKA) for Atrial Fibrillation in Non-Dialysis Dependent Chronic Kidney Disease, PLoS ONE, vol.34, issue.5, p.94420, 2014.
DOI : 10.1371/journal.pone.0094420.t005

K. Parker, M. Vincent, and M. S. , WARFARIN MANAGEMENT IN HAEMODIALYSIS-ARE WE MEETING BRITISH HAEMATOLOGY SOCIETY STANDARDS?, Journal of Renal Care, vol.19, issue.5, pp.202-208, 2012.
DOI : 10.1681/ASN.2007030308

S. Kaatz, Determinants and measures of quality in oral anticoagulation therapy, Journal of Thrombosis and Thrombolysis, vol.146, issue.3, pp.61-67, 2007.
DOI : 10.7326/0003-4819-146-3-200702060-00150

S. Pokorney, D. Simon, L. Thomas, G. Fonarow, P. Kowey et al., Patients??? time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry, American Heart Journal, vol.170, issue.1, pp.141-148
DOI : 10.1016/j.ahj.2015.03.017

L. Quinn, R. Richardson, K. Cameron, and M. Battistella, Evaluating time in therapeutic range for hemodialysis patients taking warfarin, Clinical Nephrology, vol.83, issue.02, pp.80-85, 2015.
DOI : 10.5414/CN108400

F. Rosendaal, S. Cannegieter, F. Van-der-meer, and E. Briët, A method to determine the optimal intensity of oral anticoagulant therapy, Thromb Haemost, vol.69, issue.3, pp.236-245, 1993.

L. Schmitt, J. Speckman, and A. J. , Quality Assessment of Anticoagulation Dose Management: Comparative Evaluation of Measures of Time-in-Therapeutic Range, Journal of Thrombosis and Thrombolysis, vol.15, issue.3, pp.213-219
DOI : 10.1023/B:THRO.0000011377.78585.63

S. Lamontagne, T. Basein, B. Chang, and L. Mallela, A hemodialysis cohort study of protocol-based anticoagulation management, BMC Research Notes, vol.6, issue.11, p.66, 2017.
DOI : 10.2215/CJN.04550511

S. Genovesi, E. Rossi, M. Gallieni, A. Stella, F. Badiali et al., Warfarin use, mortality, bleeding and stroke in haemodialysis patients with atrial fibrillation, Nephrology Dialysis Transplantation, vol.30, issue.3, pp.491-499, 2015.
DOI : 10.1093/ndt/gfu334

URL : https://academic.oup.com/ndt/article-pdf/30/3/491/17172689/gfu334.pdf

S. Connolly, M. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren et al., Dabigatran versus Warfarin in Patients with Atrial Fibrillation, New England Journal of Medicine, vol.361, issue.12, pp.1139-51, 2009.
DOI : 10.1056/NEJMoa0905561

S. Mueller, M. Pfannkuche, G. Breithardt, R. Bauersachs, U. Maywald et al., The quality of oral anticoagulation in general practice in patients with atrial fibrillation, European Journal of Internal Medicine, vol.25, issue.3
DOI : 10.1016/j.ejim.2013.12.013

R. Kheder-elfekih, C. Poitou, I. Brocheriou, H. Depreneuf, and H. Izzedine, Fluindione-induced immuno-allergic interstitial nephritis. NDT Plus, Feb, vol.2, issue.1, pp.72-77, 2009.
DOI : 10.1093/ndtplus/sfn171

URL : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4421494/pdf

A. Daveluy, B. Milpied, A. Barbaud, B. Lebrun-vignes, A. Gouraud et al., Fluindione and drug reaction with eosinophilia and systemic symptoms: an unrecognised adverse effect?, European Journal of Clinical Pharmacology, vol.43, issue.1, pp.101-106, 2012.
DOI : 10.1046/j.1365-2125.1997.05417.x

URL : https://hal.archives-ouvertes.fr/hal-00713311

W. Nelson, J. Choi, J. Vanderpoel, C. Damaraju, P. Wildgoose et al., Impact of Co-morbidities and Patient Characteristics on International Normalized Ratio Control Over Time in Patients With Nonvalvular Atrial Fibrillation, The American Journal of Cardiology, vol.112, issue.4, pp.509-521, 2013.
DOI : 10.1016/j.amjcard.2013.04.013

Y. Sun, Z. Wu, S. Li, X. Qin, T. Li et al., Impact of gamma-glutamyl carboxylase gene polymorphisms on warfarin dose requirement: A systematic review and meta-analysis, Thrombosis Research, vol.135, issue.4
DOI : 10.1016/j.thromres.2015.01.029

N. Jourde-chiche, L. Dou, C. Cerini, F. Dignat-george, and P. Brunet, Vascular Incompetence in Dialysis Patients?Protein-Bound Uremic Toxins and Endothelial Dysfunction. Semin Dial, pp.327-364, 2011.
DOI : 10.1111/j.1525-139x.2011.00925.x

URL : https://hal.archives-ouvertes.fr/hal-01610435

C. Herzog, R. Asinger, A. Berger, D. Charytan, J. Díez et al., Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO), Kidney International, vol.80, issue.6, pp.572-86, 2011.
DOI : 10.1038/ki.2011.223